Articles

Megabanks not immune to office space slowdown as stressed loan percentage jumps

FDIC Chairman Martin Gruenberg sees ‘downside risk for the industry’

U.S. industrial output inches up 0.1% in February after sharp decline in prior month

Industrial production rose 0.1% in February, the Federal Reserve reported Friday. The gain was above expectations of a flat reading, according to a survey by The Wall Street Journal.

Steel Dynamics sees ‘meaningfully stronger’ profit amid broad demand growth

The continued return of manufacturing to the U.S., coupled with the “robust” U.S. infrastructure program, will support strong demand for years.

Snowflake’s stock draws upgrade after steep decline, but it’s hardly effusive

A Guggenheim analyst still sees a “mountain of challenges” but says Snowflake’s full-year forecast looks beatable.

Manufacturing activity falls significantly in New York in March

The New York Fed’s Empire State business-conditions index, a gauge of manufacturing activity in the state, fell 18.5 points in March to negative 20.9, the regional bank said Friday.

Import prices rise for second month in a row and add to U.S. inflation

The cost of imported goods rose in February for the second month in a row and added to a small upturn in U.S. inflation early in the new year.

‘Now is the time of monsters.’ One central-bank chief has doubts about the dollar’s hegemony.

One central bank head reportedly quoted the Italian philosopher Antonio Gramsci about the dollar’s dominance on the world stage: “The old world is dying, and the new world struggles to be born: now is the time of monsters.”

Jabil gives downbeat earnings outlook, sending its stock lower

Jabil called out “revenue headwinds” as it posted slightly disappointing top-line results for its latest quarter and issued a downbeat outlook.

What does your spouse want in retirement? 6 questions to ask.

Spouses often have different expectations that can be harmonized

BlackRock launches U.S. equity ETFs with covered-call strategies as option-based funds surge

BlackRock is rolling out two new exchange-traded funds that use option strategies, a hot area of the ETF market in the U.S.

Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia

Bristol Myers Squibb’s cell therapy Breyanzi won FDA approval Thursday for treatment of a common type of leukemia.

Hibbett’s stock falls 8.9% after earnings and guidance fall short of estimates

Hibbett’s stock fell premarket Friday after the company, which is working with Nike, missed earnings expectations in its latest quarter.
1 691 692 693 694 695 1,648